These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20061790)

  • 1. Recombinant protein vaccines against the asexual blood stages of Plasmodium falciparum.
    Anders RF; Adda CG; Foley M; Norton RS
    Hum Vaccin; 2010 Jan; 6(1):39-53. PubMed ID: 20061790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.
    Biswas S; Spencer AJ; Forbes EK; Gilbert SC; Holder AA; Hill AV; Draper SJ
    J Immunol; 2012 May; 188(10):5041-53. PubMed ID: 22504652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.
    Terheggen U; Drew DR; Hodder AN; Cross NJ; Mugyenyi CK; Barry AE; Anders RF; Dutta S; Osier FH; Elliott SR; Senn N; Stanisic DI; Marsh K; Siba PM; Mueller I; Richards JS; Beeson JG
    BMC Med; 2014 Oct; 12():183. PubMed ID: 25319190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion.
    Kocken CH; Withers-Martinez C; Dubbeld MA; van der Wel A; Hackett F; Valderrama A; Blackman MJ; Thomas AW
    Infect Immun; 2002 Aug; 70(8):4471-6. PubMed ID: 12117958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.
    Tamminga C; Sedegah M; Maiolatesi S; Fedders C; Reyes S; Reyes A; Vasquez C; Alcorta Y; Chuang I; Spring M; Kavanaugh M; Ganeshan H; Huang J; Belmonte M; Abot E; Belmonte A; Banania J; Farooq F; Murphy J; Komisar J; Richie NO; Bennett J; Limbach K; Patterson NB; Bruder JT; Shi M; Miller E; Dutta S; Diggs C; Soisson LA; Hollingdale MR; Epstein JE; Richie TL
    Hum Vaccin Immunother; 2013 Oct; 9(10):2165-77. PubMed ID: 23899517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2.
    Krishnarjuna B; Andrew D; MacRaild CA; Morales RA; Beeson JG; Anders RF; Richards JS; Norton RS
    Sci Rep; 2016 Feb; 6():20613. PubMed ID: 26865062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
    Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
    Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
    Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
    Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria.
    Stowers AW; Kennedy MC; Keegan BP; Saul A; Long CA; Miller LH
    Infect Immun; 2002 Dec; 70(12):6961-7. PubMed ID: 12438375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.
    Polley SD; Conway DJ; Cavanagh DR; McBride JS; Lowe BS; Williams TN; Mwangi TW; Marsh K
    Vaccine; 2006 May; 24(19):4233-46. PubMed ID: 16111789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria.
    Drew DR; Hodder AN; Wilson DW; Foley M; Mueller I; Siba PM; Dent AE; Cowman AF; Beeson JG
    PLoS One; 2012; 7(12):e51023. PubMed ID: 23227229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of Aotus monkeys after immunization with recombinant antigens of Plasmodium falciparum.
    Enders B; Hundt E; Knapp B
    Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():413-22. PubMed ID: 1343721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.
    Longley RJ; Halbroth BR; Salman AM; Ewer KJ; Hodgson SH; Janse CJ; Khan SM; Hill AVS; Spencer AJ
    Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28031267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.
    Miura K; Herrera R; Diouf A; Zhou H; Mu J; Hu Z; MacDonald NJ; Reiter K; Nguyen V; Shimp RL; Singh K; Narum DL; Long CA; Miller LH
    Infect Immun; 2013 May; 81(5):1491-501. PubMed ID: 23429537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine.
    Ouattara A; Mu J; Takala-Harrison S; Saye R; Sagara I; Dicko A; Niangaly A; Duan J; Ellis RD; Miller LH; Su XZ; Plowe CV; Doumbo OK
    Malar J; 2010 Jun; 9():175. PubMed ID: 20565971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccinating with the genome: a Sisyphean task?
    Coppel RL
    Trends Parasitol; 2009 May; 25(5):205-12. PubMed ID: 19359219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.
    Kennedy MC; Wang J; Zhang Y; Miles AP; Chitsaz F; Saul A; Long CA; Miller LH; Stowers AW
    Infect Immun; 2002 Dec; 70(12):6948-60. PubMed ID: 12438374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.